Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Introduction.

March L, Richards B, Gill M, Brooks PM, Shea BJ, Beaton DE, Maxwell LJ, Tunis SR, Grosskleg S, Tugwell P.

J Rheumatol. 2019 Aug;46(8):962-968. doi: 10.3899/jrheum.190105. No abstract available.

PMID:
31371663
2.

The increasing complexity of the core outcomes landscape.

Moloney RM, Messner DA, Tunis SR.

J Clin Epidemiol. 2019 May 23. pii: S0895-4356(18)30994-6. doi: 10.1016/j.jclinepi.2019.05.016. [Epub ahead of print]

PMID:
31129260
3.

Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets.

Tunis SR, Maxwell LJ, Graham ID, Shea BJ, Beaton DE, Bingham CO 3rd, Brooks P, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2017 Oct;44(10):1551-1559. doi: 10.3899/jrheum.161273. Epub 2017 Aug 1.

4.

Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research.

Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP.

Genet Med. 2017 Oct;19(10):1081-1091. doi: 10.1038/gim.2017.21. Epub 2017 Apr 13. Review.

5.

Payer Perspectives on Coverage of Biomarker Testing in Cardiovascular Disease.

Tunis SR, Messner DA.

Clin Chem. 2017 Jan;63(1):258-260. doi: 10.1373/clinchem.2016.268136. Epub 2016 Nov 18. No abstract available.

6.

Improving the relevance and consistency of outcomes in comparative effectiveness research.

Tunis SR, Clarke M, Gorst SL, Gargon E, Blazeby JM, Altman DG, Williamson PR.

J Comp Eff Res. 2016 Mar;5(2):193-205. doi: 10.2217/cer-2015-0007. Epub 2016 Mar 1. Review.

7.

Patient and clinician support for the learning healthcare system: recommendations for enhancing value.

Moloney RM, Tambor ES, Tunis SR.

J Comp Eff Res. 2016 Mar;5(2):123-8. doi: 10.2217/cer.15.67. Epub 2016 Mar 1. Review. No abstract available.

8.

Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology.

Deverka P, Messner DA, McCormack R, Lyman GH, Piper M, Bradley L, Parkinson D, Nelson D, McLeod HL, Smith ML, Jacques L, Dutta T, Tunis SR.

Genet Med. 2016 Aug;18(8):780-7. doi: 10.1038/gim.2015.162. Epub 2015 Dec 3. Erratum in: Genet Med. 2016 Jun;18(6):650.

PMID:
26633547
9.

Medical and pharmacy coverage decision making at the population level.

Mohr PE, Tunis SR.

J Manag Care Spec Pharm. 2014 Jun;20(6):547-54.

10.

Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer.

Parkinson DR, McCormack RT, Keating SM, Gutman SI, Hamilton SR, Mansfield EA, Piper MA, Deverka P, Frueh FW, Jessup JM, McShane LM, Tunis SR, Sigman CC, Kelloff GJ.

Clin Cancer Res. 2014 Mar 15;20(6):1428-44. doi: 10.1158/1078-0432.CCR-13-2961.

11.

Interview: a 20-year 'search for evidence' leads to the Center for Medical Technology Policy.

Tunis SR.

J Comp Eff Res. 2014 Jan;3(1):11-6. doi: 10.2217/cer.13.88. No abstract available.

12.

Lack of evidence for clinical and health policy decisions.

Tunis SR.

BMJ. 2013 Dec 16;347:f7155. doi: 10.1136/bmj.f7155. No abstract available.

PMID:
24343113
13.

Medicare policy on bariatric surgery: decision making in the face of uncertainty.

Tunis SR, Messner DA.

JAMA. 2013 Oct 2;310(13):1339-40. doi: 10.1001/jama.2013.278849. No abstract available.

PMID:
24030634
14.

Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payers.

Sonnad SS, Mullins CD, Whicher D, Goldsack JC, Mohr PE, Tunis SR.

Contemp Clin Trials. 2013 Nov;36(2):356-61. doi: 10.1016/j.cct.2013.08.008. Epub 2013 Aug 31.

PMID:
23999501
15.

Encouraging value-based insurance designs in state health insurance exchanges.

Buttorff C, Tunis SR, Weiner JP.

Am J Manag Care. 2013 Jul;19(7):593-600.

16.

Breaking a vicious cycle.

Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR.

Sci Transl Med. 2013 Jul 31;5(196):196cm6. doi: 10.1126/scitranslmed.3005950.

PMID:
23903752
17.

Using health technology assessment to identify gaps in evidence and inform study design for comparative effectiveness research.

Tunis SR, Turkelson C.

J Clin Oncol. 2012 Dec 1;30(34):4256-61. doi: 10.1200/JCO.2012.42.6338. Epub 2012 Oct 15. Review.

PMID:
23071248
18.

Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update.

Veenstra DL, Piper M, Haddow JE, Pauker SG, Klein R, Richards CS, Tunis SR, Djulbegovic B, Marrone M, Lin JS, Berg AO, Calonge N.

Genet Med. 2013 Jan;15(1):14-24. doi: 10.1038/gim.2012.106. Epub 2012 Sep 6. Review.

19.

Improving comparative effectiveness research.

Tunis SR.

BMJ. 2012 Aug 1;345:e5160. doi: 10.1136/bmj.e5160. No abstract available.

PMID:
22859777
20.

Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States.

Saag KG, Mohr PE, Esmail L, Mudano AS, Wright N, Beukelman T, Curtis JR, Cutter G, Delzell E, Gary LC, Harrington TM, Karkare S, Kilgore ML, Lewis CE, Moloney R, Oliveira A, Singh JA, Warriner A, Zhang J, Berger M, Cummings SR, Pace W, Solomon DH, Wallace R, Tunis SR.

Contemp Clin Trials. 2012 Nov;33(6):1211-6. doi: 10.1016/j.cct.2012.07.002. Epub 2012 Jul 5.

21.

Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement.

Deverka PA, Lavallee DC, Desai PJ, Esmail LC, Ramsey SD, Veenstra DL, Tunis SR.

J Comp Eff Res. 2012 Mar;1(2):181-194.

22.

Incorporating stakeholder perspectives in developing a translation table framework for comparative effectiveness research.

Gliklich RE, Leavy MB, Velentgas P, Dreyer NA, Tunis SR, Mohr P, Messner DA, Moloney RM, Karkare SU, Dubois RW, Graff JS.

J Comp Eff Res. 2012 May;1(3):281-92. doi: 10.2217/cer.12.25.

PMID:
24237409
23.

A translation table for patient-centered comparative effectiveness research: guidance to improve the value of research for clinical and health policy decision-making.

Tunis SR, Messner DA, Mohr P, Gliklich RE, Dubois RW.

J Comp Eff Res. 2012 May;1(3):259-62. doi: 10.2217/cer.12.22.

24.

How well do randomized trials inform decision making: systematic review using comparative effectiveness research measures on acupuncture for back pain.

Witt CM, Manheimer E, Hammerschlag R, L├╝dtke R, Lao L, Tunis SR, Berman BM.

PLoS One. 2012;7(2):e32399. doi: 10.1371/journal.pone.0032399. Epub 2012 Feb 28. Review.

25.

Current and future state of FDA-CMS parallel reviews.

Messner DA, Tunis SR.

Clin Pharmacol Ther. 2012 Mar;91(3):383-5. doi: 10.1038/clpt.2011.350.

PMID:
22343814
26.

A framework for pharmaceutical value-based innovations.

Salimi T, Lehner JP, Epstein RS, Tunis SR.

J Comp Eff Res. 2012 Jan;1(1 Suppl):3-7. doi: 10.2217/cer.11.2.

PMID:
24237316
27.

How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment.

Ramsey SD, Veenstra D, Tunis SR, Garrison L, Crowley JJ, Baker LH.

Health Aff (Millwood). 2011 Dec;30(12):2259-68. doi: 10.1377/hlthaff.2010.0637.

28.

Informatics in action: lessons learned in comparative effectiveness research.

Hirsch BR, Giffin RB, Esmail LC, Tunis SR, Abernethy AP, Murphy SB.

Cancer J. 2011 Jul-Aug;17(4):235-8. doi: 10.1097/PPO.0b013e31822c3944. Review.

PMID:
21799331
29.

A policy approach to the development of molecular diagnostic tests.

Schulman KA, Tunis SR.

Nat Biotechnol. 2010 Nov;28(11):1157-9. doi: 10.1038/nbt1110-1157.

PMID:
21057480
30.

How best to engage patients, doctors, and other stakeholders in designing comparative effectiveness studies.

Hoffman A, Montgomery R, Aubry W, Tunis SR.

Health Aff (Millwood). 2010 Oct;29(10):1834-41. doi: 10.1377/hlthaff.2010.0675.

PMID:
20921483
31.

Why observational studies should be among the tools used in comparative effectiveness research.

Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox P, Gliklich R.

Health Aff (Millwood). 2010 Oct;29(10):1818-25. doi: 10.1377/hlthaff.2010.0666.

PMID:
20921481
32.

US moves to improve health decisions.

Tunis SR, Pearson SD.

BMJ. 2010 Aug 23;341:c3615. doi: 10.1136/bmj.c3615. No abstract available.

PMID:
20732966
33.

Comparative effectiveness research: Policy context, methods development and research infrastructure.

Tunis SR, Benner J, McClellan M.

Stat Med. 2010 Aug 30;29(19):1963-76. doi: 10.1002/sim.3818.

PMID:
20564311
34.

Medicare and medical technology--the growing demand for relevant outcomes.

Neumann PJ, Tunis SR.

N Engl J Med. 2010 Feb 4;362(5):377-9. doi: 10.1056/NEJMp0912062. Epub 2010 Jan 20. No abstract available.

PMID:
20089955
35.

Access with evidence development: the US experience.

Mohr PE, Tunis SR.

Pharmacoeconomics. 2010;28(2):153-62. doi: 10.2165/11531050-000000000-00000.

PMID:
20085391
36.

Does comparative-effectiveness research threaten personalized medicine?

Garber AM, Tunis SR.

N Engl J Med. 2009 May 7;360(19):1925-7. doi: 10.1056/NEJMp0901355. No abstract available.

PMID:
19420360
37.

Crossroads in quality.

O'Kane M, Corrigan J, Foote SM, Tunis SR, Isham GJ, Nichols LM, Fisher ES, Ebeler JC, Block JA, Bradley BE, Cassel CK, Ness DL, Tooker J.

Health Aff (Millwood). 2008 May-Jun;27(3):749-58. doi: 10.1377/hlthaff.27.3.749.

PMID:
18474968
38.

Challenges in Australian policy processes for disinvestment from existing, ineffective health care practices.

Elshaug AG, Hiller JE, Tunis SR, Moss JR.

Aust New Zealand Health Policy. 2007 Oct 31;4:23.

39.

Coverage with evidence development: a very good beginning, but much to be done. Commentary to Hutton et al.

Tunis SR, Chalkidou K.

Int J Technol Assess Health Care. 2007 Fall;23(4):432-5. No abstract available.

PMID:
17937830
40.

The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development.

Lindsay MJ, Siegel BA, Tunis SR, Hillner BE, Shields AF, Carey BP, Coleman RE.

AJR Am J Roentgenol. 2007 Apr;188(4):1109-13.

PMID:
17377055
41.

Federal initiatives to support rapid learning about new technologies.

Tunis SR, Carino TV, Williams RD 2nd, Bach PB.

Health Aff (Millwood). 2007 Mar-Apr;26(2):w140-9. Epub 2007 Jan 26. Review.

PMID:
17259196
42.

Coverage options for promising technologies: Medicare's 'coverage with evidence development'.

Tunis SR, Pearson SD.

Health Aff (Millwood). 2006 Sep-Oct;25(5):1218-30.

PMID:
16966717
43.

Controlled trial of interventions to increase testing and treatment for Helicobacter pylori and reduce medication use in patients with chronic acid-related symptoms.

Majumdar SR, Ross-Degnan D, Farraye FA, Lee M, Kemp JA, Lecates RF, Henning JM, Tunis SR, Schrammel P, Soumerai SB.

Aliment Pharmacol Ther. 2005 Apr 15;21(8):1029-39.

44.

Medicare coverage of ICDs.

McClellan MB, Tunis SR.

N Engl J Med. 2005 Jan 20;352(3):222-4. No abstract available.

PMID:
15659721
45.

A clinical research strategy to support shared decision making.

Tunis SR.

Health Aff (Millwood). 2005 Jan-Feb;24(1):180-4.

PMID:
15647229
46.

Economic analysis in healthcare decisions.

Tunis SR.

Am J Manag Care. 2004 May;10(5):301-4. No abstract available.

47.

Why Medicare has not established criteria for coverage decisions.

Tunis SR.

N Engl J Med. 2004 May 20;350(21):2196-8. No abstract available.

PMID:
15152066
48.
49.

Improvements in medicare coverage of new technology.

Tunis SR, Kang JL.

Health Aff (Millwood). 2001 Sep-Oct;20(5):83-5. No abstract available.

PMID:
11558723
50.

Lansoprazole compared with histamine2-receptor antagonists in healing gastric ulcers: a meta-analysis.

Tunis SR, Sheinhait IA, Schmid CH, Bishop DJ, Ross SD.

Clin Ther. 1997 Jul-Aug;19(4):743-57.

PMID:
9377618

Supplemental Content

Loading ...
Support Center